300 related articles for article (PubMed ID: 21824072)
41. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
42. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
43. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
44. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
46. Mepolizumab-based therapy in asthma: an update.
Walsh GM
Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
[TBL] [Abstract][Full Text] [Related]
47. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
48. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
49. Eosinophilia in Pulmonary Disorders.
Woolnough K; Wardlaw AJ
Immunol Allergy Clin North Am; 2015 Aug; 35(3):477-92. PubMed ID: 26209896
[TBL] [Abstract][Full Text] [Related]
50. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
51. Clinical manifestations and treatment of Churg-Strauss syndrome.
Baldini C; Talarico R; Della Rossa A; Bombardieri S
Rheum Dis Clin North Am; 2010 Aug; 36(3):527-43. PubMed ID: 20688248
[TBL] [Abstract][Full Text] [Related]
52. Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.
Paton DM
Drugs Today (Barc); 2016 Jun; 52(6):323-9. PubMed ID: 27458609
[TBL] [Abstract][Full Text] [Related]
53. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
54. Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia.
Lin RY; Santiago TP; Patel NM
J Asthma; 2019 Nov; 56(11):1193-1197. PubMed ID: 30395734
[No Abstract] [Full Text] [Related]
55. Eosinophilic pneumonias in children: A review of the epidemiology, diagnosis, and treatment.
Giovannini-Chami L; Blanc S; Hadchouel A; Baruchel A; Boukari R; Dubus JC; Fayon M; Le Bourgeois M; Nathan N; Albertini M; Clément A; de Blic J
Pediatr Pulmonol; 2016 Feb; 51(2):203-16. PubMed ID: 26716396
[TBL] [Abstract][Full Text] [Related]
56. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
Hassani M; Koenderman L
Allergy; 2018 Oct; 73(10):1979-1988. PubMed ID: 29611207
[TBL] [Abstract][Full Text] [Related]
57. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
58. Eosinophilic Lung Diseases.
Cottin V
Immunol Allergy Clin North Am; 2023 May; 43(2):289-322. PubMed ID: 37055090
[TBL] [Abstract][Full Text] [Related]
59. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.
Brenard E; Pilette C; Dahlqvist C; Colinet B; Schleich F; Roufosse F; Froidure A
Lung; 2020 Apr; 198(2):355-360. PubMed ID: 32052155
[TBL] [Abstract][Full Text] [Related]
60. Eosinophilic Lung Diseases.
Cottin V
Clin Chest Med; 2016 Sep; 37(3):535-56. PubMed ID: 27514599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
